Table 3 Comparison of center-involving HE and non-center-involving HE groups
Proportion of remaining HEs area, % | Month 1 | Month 2 | Month 3 | ||
|---|---|---|---|---|---|
Mean ± SD | Mean ± SD | Mean ± SD | P-value* | ||
Triamcinolone | Total | 53.5 ± 4.91 | 53.0 ± 4.66 | 52.9 ± 4.21 | 0.489 |
Center-involving HE (n = 14) | 54.1 ± 3.99 | 53.9 ± 4.03 | 53.3 ± 3.26 | ||
Non-center-involving HE (n = 11) | 52.9 ± 4.71 | 52.1 ± 4.97 | 51.8 ± 4.85 | ||
Dexamethasone implant | Total | 79.8 ± 4.10 | 70.1 ± 5.21 | 63.6 ± 6.08 | 0.823 |
Center-involving HE (n = 11) | 79.7 ± 4.31 | 69.8 ± 5.03 | 61.9 ± 5.97 | ||
Non-center-involving HE (n = 9) | 78.0 ± 3.17 | 70.3 ± 4.86 | 64.8 ± 6.34 | ||
Bevacizumab | Total | 92.4 ± 3.31 | 89.0 ± 4.12 | 85.2 ± 5.07 | 0.849 |
Center-involving HE (n = 13) | 92.3 ± 3.24 | 88.3 ± 3.31 | 84.2 ± 6.12 | ||
Non-center-involving HE (n = 12) | 92.6 ± 2.53 | 90.5 ± 4.77 | 86.3 ± 4.29 | ||